European Prevention of Alzheimer’s Dementia
The European Prevention of Alzheimer’s Dementia (EPAD) project aims to develop an infrastructure that efficiently enables the undertaking of adaptive, multi-arm Proof of Concept studies for early and accurate decisions on the ongoing development of drug candidates or drug combinations. This includes evaluating patients’ reactions to a drug early in a clinical trial and modifying the trial according to these reactions. The EPAD project will initially run for five years.
The EPAD programme has an initial budget of €64M distributed across a total of 35 partners from the private and academic sectors, mainly sponsored by the European Commission and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative Joint Undertaking (IMI JU).
EPAD’s introduction movie
[arve url=”https://synapse-managers.com/wp-content/uploads/2017/03/Epad_Introduction_UK.mp4″ title=”EPAD’s introduction movie” align=”right” maxwidth=”755px” play_icon_style=”youtube” thumbnail=”2343″]